First-in-Class ATR Inhibitor as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
J. Clin. Oncol 2020 Jun 22;[EPub Ahead of Print], TA Yap, B O'Carrigan, MS Penney, JS Lim, JS Brown, MJ de Miguel Luken, N Tunariu, R Perez-Lopez, DN Rodrigues, R Riisnaes, I Figueiredo, S Carreira, B Hare, K McDermott, S Khalique, CT Williamson, R Natrajan, SJ Pettitt, CJ Lord, U Banerji, J Pollard, J Lopez, JS de BonoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.